
News|Articles|October 3, 2026
Q3 2026 Recap: Allergy News and Updates
Author(s)Chelsie Derman
Fact checked by: Tim Smith
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
Advertisement
Advertisement
Related to this article

Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.

Dexmedetomidine sublingual film is the first FDA-approved at-home option for acute agitation, based on the phase 3 SERENITY at-home trial.

No patients with alpha-gal syndrome needed epinephrine for a food reaction during omalizumab therapy in a 64-patient cohort presented at ACAAI 2026.

Approval of obinutuzumab for adults with PMN follows MAJESTY, where 37% vs 6% achieved complete remission at week 104 vs tacrolimus.

A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.

HIBISCUS showed a 48.7% vs 7.2% hemoglobin response at week 24, with an FDA decision expected in 2027.

Post hoc analyses at ACAAI 2026 show 41.7% of patients-maintained CSU control and quality of life 16 weeks after stopping omalizumab.
Advertisement
Advertisement

